Echosens开通孟买中心, 使用FibroScan技术在南亚扩大肝脏疾病测试。 Echosens opens Mumbai hub to expand liver disease testing in South Asia using its FibroScan technology.

Echosens在印度孟买开设了一个新的区域总部,以扩大其在南亚各地的非侵入性肝脏诊断存在,包括印度、孟加拉国、不丹、马尔代夫、尼泊尔和斯里兰卡。 Echosens has opened a new regional headquarters in Mumbai, India, to expand its non-invasive liver diagnostics presence across South Asia, including India, Bangladesh, Bhutan, the Maldives, Nepal, and Sri Lanka. 该设施将支持业务、销售、培训和通过30多个当地伙伴进行分配,以期改进对肝病的早期发现和管理,如MASLD,这种疾病影响到本区域越来越多的成人和儿童。 The facility will support operations, sales, training, and distribution through more than 30 local partners, aiming to improve early detection and management of liver diseases like MASLD, which affects a growing number of adults and children in the region. 该举动强调Echosens承诺通过广泛使用的FibroScan技术解决肝病负担日益加重的问题,并以超过5,600项研究为后盾,在127多个国家使用。 The move underscores Echosens’ commitment to addressing the rising burden of liver disease through its widely used FibroScan technology, backed by over 5,600 studies and used in more than 127 countries.